Stephen Cross, MD
Ophthalmology · Columbia, SCNPI 1063737351
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 29.3% of the total. Reporting peaked in 2022 at $4,087 and has fallen 72.4% since, to $1,127 in 2025.
Across 202 payments — averaging $54.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$3K
- Glaukos Corporation$3K
- Sun Pharmaceutical Industries Inc.$1K
- Alcon$745
- AbbVie$525
- Sight Sciences, Inc.$430
- plus $2K from 19 others
What the payments were for
- Consulting fees$5,37549%
- Speaking & faculty fees$280%
- Food & beverage$5,65951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 7 | $3,238 |
| Glaukos Corporation | 9 | $3,123 |
| Sun Pharmaceutical Industries Inc. | 63 | $1,009 |
| Alcon | 30 | $745 |
| AbbVie(2 entities) | 17 | $525 |
| Sight Sciences, Inc. | 9 | $430 |
| Bausch & Lomb Americas Inc. | 10 | $328 |
| Novartis | 11 | $256 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $223 |
| Rayner Intraocular Lenses Limited | 10 | $214 |
| Ivantis, Inc | 5 | $147 |
| Dompe US, Inc. | 7 | $144 |
| Rxsight Inc | 3 | $141 |
| Omeros Corporation | 1 | $125 |
| NEW World Medical,inc. | 1 | $107 |
| Amgen(2 entities) | 4 | $65 |
| Kala Pharmaceuticals, Inc. | 2 | $63 |
| Tarsus Pharmaceuticals, Inc. | 1 | $33 |
| Hoffmann-la Roche Limited | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Oyster Point Pharma, Inc. | 1 | $25 |
| Ocular Therapeutix, Inc. | 1 | $21 |
| Biotissue Holdings Inc. | 2 | $20 |
| Aerie Pharmaceuticals, Inc. | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$6,048
- KXL System$2,649
- OMNI(R) SURGICAL SYSTEM (US)$232
- MIEBO$227
- iStent inject W$174
- Photrexa$174
- DURYSTA$126
- OMIDRIA$125
- CEQUA$125
- XIIDRA$123
- AcrySof IQ VIVITY$116
- Kahook Dual Blade$107
- Clearpath$107
- Ahmed Glaucoma Valve$107
- Streamline$107
- Via360$107
- Clareon PanOptix Pro$106
- Hydrus Microstent$103
How this compares
$11,062 in reported general payments places this provider in the 85th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 58 | $76,506 |
| RestasisCyclosporine | 58 | $56,143 |
| MieboPerfluorohexyloctane/Pf | 35 | $27,644 |
| CequaCyclosporine | 29 | $26,005 |
| ProlensaBromfenac Sodium | 71 | $25,051 |
| Bromfenac Sodium | 127 | $24,561 |
| IlevroNepafenac | 67 | $24,513 |
| Cyclosporine | 41 | $22,704 |
| Prednisolone Acetate | 419 | $20,538 |
| TyrvayaVarenicline Tartrate | 19 | $12,621 |
| Fluorometholone | 113 | $10,330 |
| LumiganBimatoprost | 18 | $8,917 |
| CombiganBrimonidine Tartrate/Timolol | 33 | $8,010 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $6,031 |
| Brimonidine Tartrate | 229 | $5,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $328 | $104,15093 claims |
| AbbVieRestasis, Lumigan, Combigan | $525 | $73,071109 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $223 | $28,86094 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,009 | $26,00529 claims |
| NovartisIlevro | $256 | $24,51367 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $25 | $12,62119 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $20 | $6,03115 claims |
| Eyevance Pharmaceuticals LLCFlarex | $12 | $1,80913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Columbia
- Matthew ClaryColumbia$119K
- Willard HarmsColumbia$14K
- Robert HuffColumbia$13K
- Ryan MercerColumbia$9K
- Lucas PlattColumbia$7K
- Kerry SolomonMt Pleasant$1.7M
- William ClarkWest Columbia$768K
- George WaringMt Pleasant$645K
- Karolinne RochaCharleston$552K
- Joseph BishopHilton Head Island$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.